Syngene Q1 FY22 revenue grows 41%
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
Subscribe To Our Newsletter & Stay Updated